What is Qiagen N.V. (QGEN)?

Qiagen N.V. (QGEN) is a stock in the Healthcare sector, Medical - Diagnostics & Research industry. View full analysis on Stocks360.

What is the current price of QGEN?

The current price of QGEN is $50.26. Prices are updated in real time on Stocks360.

What is QGEN's price-to-earnings (PE) ratio?

QGEN's trailing twelve-month PE ratio is 25.77, based on current price and earnings per share data available on Stocks360.

What is QGEN's market capitalization?

QGEN's market capitalization is $10,357,329,154.00, placing it in the large-cap tier.

Does QGEN pay a dividend?

Yes. QGEN has a trailing twelve-month dividend yield of 0.05%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Qiagen N.V. (QGEN)

Stock analysis · NYSE · Healthcare · Medical - Diagnostics & Research

$50.26

Market Cap

$10.36B

PE (TTM)

25.77

EPS (TTM)

N/A

Dividend Yield

5.25%

Beta

0.61

Day Range

$50.15 – $50.34

52-wk Range

$32.53 – $57.82

Avg Volume

N/A

Volume

1.66M

Qiagen N.V. (QGEN) is a publicly traded company in the Healthcare sector. Latest price: $50.26. Market cap $10.36B. Trailing PE 25.77. Dividend yield 5.25%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $47.95 2026-10-28 · $50.25 (+4.80%)

Earnings

Most Recent

Aug 5, 2026

EPS $0.62 vs est. $0.60

Beat by $0.02

Next Earnings

Nov 4, 2026

EPS estimate $0.63

Proprietary Signals

Signal snapshot temporarily unavailable.

About Qiagen N.V.

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	25.77×
P/S (TTM)	4.93×
P/B	3.09×
PEG	1.84×
P/FCF (TTM)	23.13×
EV / EBITDA	15.97×
EV / Sales	5.35×
Earnings Yield	3.95%
Free Cash Flow Yield	4.32%
Dividend Yield	5.25%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$11.23B
Revenue (TTM)	$2.10B
Net Income (TTM)	$408.78M
Free Cash Flow (TTM)	$475.54M
Net Debt	$875.12M
Working Capital	$1.08B
Gross Margin	61.82%
Operating Margin	25.33%
Net Margin	19.49%
Return on Equity	11.60%
Return on Invested Capital	8.86%